Capital Management Corp VA Lowers Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Capital Management Corp VA lessened its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 8.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 334,045 shares of the biotechnology company's stock after selling 31,225 shares during the period. Exelixis accounts for about 2.0% of Capital Management Corp VA's portfolio, making the stock its 21st biggest holding. Capital Management Corp VA owned about 0.12% of Exelixis worth $11,124,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Banco Santander S.A. bought a new position in shares of Exelixis in the 4th quarter worth about $809,000. Machina Capital S.A.S. bought a new stake in Exelixis in the 4th quarter valued at about $206,000. Edgestream Partners L.P. raised its stake in Exelixis by 50.7% during the 4th quarter. Edgestream Partners L.P. now owns 110,293 shares of the biotechnology company's stock worth $3,673,000 after buying an additional 37,085 shares during the period. Jackson Creek Investment Advisors LLC bought a new position in Exelixis in the fourth quarter worth approximately $301,000. Finally, Ashton Thomas Private Wealth LLC bought a new position in Exelixis in the fourth quarter worth approximately $240,000. Institutional investors own 85.27% of the company's stock.

Exelixis Price Performance

NASDAQ:EXEL traded up $0.27 during trading hours on Wednesday, hitting $37.20. The company had a trading volume of 2,751,489 shares, compared to its average volume of 2,087,865. The stock has a 50-day moving average price of $35.18 and a 200 day moving average price of $32.29. The company has a market capitalization of $10.41 billion, a PE ratio of 21.02, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on EXEL shares. Stifel Nicolaus lifted their price target on shares of Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research report on Wednesday, February 12th. Wells Fargo & Company downgraded Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 price objective for the company. in a research note on Monday, February 24th. Brookline Capital Management initiated coverage on shares of Exelixis in a research report on Monday, December 23rd. They issued a "buy" rating on the stock. Truist Financial boosted their price objective on Exelixis from $42.00 to $43.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Finally, Morgan Stanley raised shares of Exelixis from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $30.00 to $40.00 in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.24.

Insider Transactions at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares of the company's stock, valued at $1,060,561.28. This represents a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bob Oliver sold 18,647 shares of the firm's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total value of $694,600.75. Following the transaction, the director now directly owns 33,514 shares of the company's stock, valued at $1,248,396.50. This represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,343 shares of company stock valued at $5,177,234. Corporate insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.